Article info
PDFSection 2: Selection, Procurement and Distribution
2SPD-009 Cost minimisation study of the biological treatment of inflammatory bowel disease: ustekinumab versus vedolizumab
Citation
2SPD-009 Cost minimisation study of the biological treatment of inflammatory bowel disease: ustekinumab versus vedolizumab
Publication history
- First published March 24, 2020.
Online issue publication
August 05, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.